Tau seeding and propagation represents one of the most compelling mechanistic frameworks for understanding the progression of tauopathies, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease[1][2]. The tau protein, normally a microtubule-stabilizing agent in neurons, undergoes pathological aggregation into neurofibrillary tangles (NFTs) that spread throughout the brain in a characteristic pattern that correlates with clinical disease progression[3].
The prion-like propagation hypothesis suggests that misfolded tau aggregates can act as "seeds" that template the conformational conversion of native tau proteins into pathological isoforms, enabling the spread of pathology from affected brain regions to anatomically connected areas[4][5]. This mechanism explains the stereotypical progression of tau pathology observed in vivo using positron emission tomography (PET) imaging with tau ligands such as [^18F]flortaucipir[6].
The MAPT (Microtubule-Associated Protein Tau) gene located on chromosome 17q21 encodes the tau protein, which exists in six isoforms ranging from 352 to 441 amino acids in the human brain[7][8]. These isoforms result from alternative splicing of exons 2, 3, and 10, with exon 10 splicing producing tau isoforms with either three (3R tau) or four (4R tau) microtubule-binding repeat domains.
In its normal physiological state, tau protein:
Pathological tau undergoes numerous post-translational modifications that promote aggregation:
Phosphorylation: Hyperphosphorylation at multiple serine, threonine, and tyrosine residues reduces tau's affinity for microtubules and promotes aggregation[9]. Key phosphorylation sites include:
Acetylation: Acetylation at Lysine residues (particularly K280 and K369) inhibits tau aggregation and promotes clearance[10].
Truncation: Proteolytic cleavage by caspases and calpains produces truncated tau fragments that serve as seeds for aggregation[11].
Ubiquitination and SUMOylation: These modifications regulate tau degradation and aggregation propensity[12].
The transition from soluble tau to insoluble aggregates requires a nucleation event that overcomes a kinetic barrier[13]. This process involves:
Cryo-electron microscopy (cryo-EM) studies have revealed distinct tau filament structures across different tauopathies[14][15]:
These structural differences may determine the clinical phenotype and regional vulnerability to pathology.
Tau aggregates can be released from neurons through multiple mechanisms[16][17]:
The prion-like spread of tau follows anatomical connectivity patterns, with synapses serving as primary transmission routes[18][19]. Synaptic activity modulates tau release:
Non-neuronal cells participate in tau propagation[20][21]:
Braak staging describes the progression of tau pathology in AD[22][23]:
This progression follows vulnerably-connected neural networks rather than simple anatomical proximity.
Tau PET imaging has revealed that pathology spreads along functional brain networks[24][25]:
Tauopathies beyond AD show distinct propagation patterns[26]:
Cell culture systems have elucidated tau seeding mechanisms[27][28]:
Animal models recapitulate key features of tau propagation[29][30]:
Characterized synthetic tau fibrils enable controlled experimentation[31]:
Tau aggregates exhibit strain-like properties similar to prions[32][33]:
Different tau strains may determine disease phenotypes[34]:
Interrupting tau propagation represents a promising therapeutic strategy[35][36]:
Small molecule inhibitors:
Monoclonal antibodies:
Gene therapy approaches:
Multiple clinical trials target tau pathology in AD and PSP[37][38]:
Key obstacles remain in tau-targeted therapies[39][40]:
Cerebrospinal fluid and blood biomarkers reflect tau pathology[41][42]:
Tau PET provides in vivo visualization of pathology[43][44]:
The MAPT gene provides insights into tau biology[45][46]:
Additional genetic factors influence tau pathology[47][48]:
Mathematical models describe tau spread[49][50]:
AI-based methods enhance prediction[51][52]:
Tau pathology triggers microglial responses that modulate disease progression[53][54]:
Inflammatory cytokines interact with tau pathology[55]:
Tau pathology impairs neuronal metabolism[56][57]:
Metabolic dysfunction intersects with tau pathology[58]:
Epidemiological studies reveal sex differences in tauopathies[59][60]:
Biological sex affects tau biology[61]:
Identifying tau pathology before symptom onset enables early intervention[62]:
Lifestyle modifications may reduce tau propagation risk[63]:
The field continues to evolve with novel approaches[64][65]:
Personalized tau-targeting strategies will transform treatment[66]:
Tau seeding and propagation represents a fundamental pathological mechanism underlying the progression of neurodegenerative tauopathies. The prion-like spread of tau pathology through anatomically connected neural networks provides a framework for understanding disease staging and clinical progression. The molecular understanding of tau nucleation, aggregation, and cell-to-cell transmission has advanced dramatically through cryo-EM studies, experimental models, and neuroimaging. Continued research into the molecular mechanisms of tau aggregation and cell-to-cell transmission will enable the development of disease-modifying therapies targeting this critical pathway.
Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. 2007. ↩︎
Guo JL, Lee VM. Cell-to-cell transmission of pathogenic tau in tauopathies. 2014. ↩︎
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. 1991. ↩︎
Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. 2013. ↩︎
Prusiner SB. Cell biology. 2012. ↩︎
Xia CF, Arteaga J, Chen G, et al. '[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer''s disease'. 2013. ↩︎
Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. 'Multiple isoforms of human tau: cDNA cloning and expression of alternative isoforms from a single gene'. 1989. ↩︎
Andreadis A, Brown WM, Kosik KS. Structure and alternative splicing of the human tau gene. 1992. ↩︎
Hanger DP, Anderton BH, Noble W. 'Tau phosphorylation: the therapeutic challenge for neurodegenerative disease'. 2009. ↩︎
Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its aggregation and toxicity. 2013. ↩︎
Gamblin TC, Chen F, Zambrano A, et al. 'Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer''s disease'. 2003. ↩︎
Lee MJ, Lee JH, Rubinsztein DC. 'Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system'. 2013. ↩︎
Cohen SI, Linse S, Luheshi LM, et al. Nucleation of protein aggregation by amyloid fibrils. 2013. ↩︎
Fitzpatrick AW, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. 2017. ↩︎
Falcon B, Zhang W, Murzin AG, et al. Structures of filaments from Pick's disease reveal a novel tau protein fold. 2018. ↩︎
Wang Y, Martinez-Vicente M, Kruger U, et al. 'Tau fragmentation, aggregation and clearance: the molecular basis for recent progress in neurobiology'. 2009. ↩︎
Sirohi K, Chiu M, Meli J, et al. Calpain-mediated tau cleavage and aggregation in neuronal cells. 2023. ↩︎
Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau in vivo. 2012. ↩︎
Calafate S, Buist A, Miskiewicz K, et al. Synaptic contacts enhance cell-to-cell tau pathology propagation. 2015. ↩︎
Hopp SC, Lin Y, Oakley D, et al. The role of microglia in neuroinflammation and tau propagation. 2018. ↩︎
Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. 2015. ↩︎
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. 2006. ↩︎
Scholl M, Lockhart SN, Schonhaut DR, et al. 'PET imaging of tau pathology: relation to neuronal network and amyloid'. 2016. ↩︎
Zhou J, Gennatas ED, Kramer JH, Rankin KP, Bradshaw CR, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. 2012. ↩︎
Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. 2009. ↩︎
Kovacs GG, Ghetti B, Goedert M. Neuropathology of tauopathies. 2023. ↩︎
Furman JL, Vaquer-Alvarez J, Beurel E. Assessing tau propagation in cell culture models. 2019. ↩︎
Usenovic M, Niroomand S, Douse NA, et al. Internalized tau seeds are principally degraded by the proteasome. 2015. ↩︎
Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. Synthetic tau fibrils mediate transmission of pathologic tau in vivo and in vitro. 2013. ↩︎
Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. 2009. ↩︎
Furukawa Y, Kaneko K, Nagai K, Onodera O. Tau protein becomes insoluble and minimally phosphorylated in the brain parenchyma with aging. 2011. ↩︎
Sanders DW, Kaufman SK, DeTure M, et al. Distinct tau prion strains propagate in cells and mice and define distinct tauopathies. 2014. ↩︎
Kaufman SK, Sanders DW, Thomas TL, et al. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. 2016. ↩︎
Chen Y, Lin Y, Davis B, et al. Tau strain diversity in human neurodegenerative diseases. 2024. ↩︎
Holtzman DM, Mandelkow E, Selkoe DJ. 'Alzheimer disease: 100 years of therapeutic advances'. 2022. ↩︎
Gerson JE, Kayed R. Therapeutic approaches targeting tau aggregation. 2020. ↩︎
Tariot PN, Lopinto E. Targeting tau for Alzheimer's disease and related neurodegenerative disorders. 2020. ↩︎
Bittar A, Sengupta U, Kayed R. Tau oligomers as pathogenic agents in Alzheimer's disease and therapeutic implications. 2022. ↩︎
Mandelkow EJ, Mandelkow E. Tau in physiology and pathology. 2014. ↩︎
Hyman BT. New neuropathological staging of Alzheimer disease. 2011. ↩︎
Blennow K, Zetterberg H. 'Biomarkers for Alzheimer''s disease: current status and prospects'. 2018. ↩︎
Zetterberg H, Bendlin BB. 'Biomarkers for Alzheimer''s disease: preparing for a new era of disease-modifying therapies'. 2021. ↩︎
Leuzy A, Chiotis K, Lemoine L, et al. 'Tau PET imaging in neurodegenerative tauopathies: a biomarker perspective'. 2022. ↩︎
Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other dementias. 2023. ↩︎
Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. 'Progressive supranuclear palsy: including the Parkinsonism variant of corticobasal degeneration'. 2023. ↩︎
Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. 2019. ↩︎
Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. 2010. ↩︎
Karch CM, Cruchaga C, Goate AM. 'Alzheimer''s disease genetics: current knowledge and future challenges'. 2014. ↩︎
Iturria-Medina Y, Sotero RC, Toussaint P, Evans AC. Epidemic spreading model to characterize misfolded proteins propagation in aging and associated brain disorders. 2016. ↩︎
Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. 2012. ↩︎
Ding J, Adolfsson O, Ramos EM, et al. Polygenic risk for Alzheimer's disease influences brain atrophy in cognitively normal elderly. 2022. ↩︎
Lee G, Nagai K, Sohn PD. 'Tau imaging: moving toward clinical utility'. 2023. ↩︎
Jayaraman A, Hameed LS, Gogineni A, et al. 'TREM2 and tau pathology: insights into the role of microglia in Alzheimer''s disease progression'. 2023. ↩︎
Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. 2017. ↩︎
Shaft-Kelley SD, Kaur G, Brown M. Cytokine modulation of tau pathology in Alzheimer's disease. 2024. ↩︎
Kandimalla R, Manczak M, Yin W, et al. Tau-induced mitochondrial dysfunction in Alzheimer's disease. 2021. ↩︎
Du F, Yu Q, Yan S, et al. PINK1, parkin, and mitochondrial quality control in neurodegeneration. 2020. ↩︎
Kellar D, Craft S. 'Brain insulin resistance in Alzheimer''s disease and related disorders: mechanisms and therapeutic approaches'. 2020. ↩︎
'Ferretti MT, Iuliano MF, T企业发展. Sex differences in Alzheimer''s disease: from epidemiology to therapeutic responses. Nat Rev Neurol. 2023;19(11):661-674'. 2023. ↩︎
Lisovich A, DeKosky ST, Ikonomovic MD. Sex differences in tau pathology and neurodegeneration. 2022. ↩︎
Chen X, Guo C, Kong J. Sex-dependent tau phosphorylation and aggregation in Alzheimer's disease. 2022. ↩︎
Ossenkoppele R, van der Flier WM, Verfaillie SC, et al. Long-term effects of amyloid, tau, and neurodegeneration on brain networks. 2020. ↩︎
Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on molecular and cognitive signs of Alzheimer's disease. 2021. ↩︎
Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, from tangles to Alzheimer disease. 2023. ↩︎
Avila J, Jimenez JS, Sayas CL, et al. Tau structures. 2024. ↩︎
Bohringer J, Luber B, Schultz J. 'Precision medicine in Alzheimer''s disease: from genetic risk to personalized treatment'. 2024. ↩︎